- Home
- HNVR vs AVTX Comparison
HNVR vs AVTX Comparison
Compare HNVR & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- AVTX
- Stock Information
- Founded
- HNVR 2008
- AVTX 2011
- Country
- HNVR United States
- AVTX United States
- Employees
- HNVR N/A
- AVTX N/A
- Industry
- HNVR Commercial Banks
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- AVTX Health Care
- Exchange
- HNVR Nasdaq
- AVTX Nasdaq
- Market Cap
- HNVR 167.7M
- AVTX 138.8M
- IPO Year
- HNVR 2022
- AVTX 2015
- Fundamental
- Price
- HNVR $22.20
- AVTX $14.22
- Analyst Decision
- HNVR Buy
- AVTX Strong Buy
- Analyst Count
- HNVR 2
- AVTX 9
- Target Price
- HNVR $23.75
- AVTX $30.14
- AVG Volume (30 Days)
- HNVR 12.8K
- AVTX 467.6K
- Earning Date
- HNVR 10-23-2025
- AVTX 11-06-2025
- Dividend Yield
- HNVR 1.78%
- AVTX N/A
- EPS Growth
- HNVR N/A
- AVTX N/A
- EPS
- HNVR 1.53
- AVTX N/A
- Revenue
- HNVR $68,211,000.00
- AVTX $441,000.00
- Revenue This Year
- HNVR N/A
- AVTX N/A
- Revenue Next Year
- HNVR $17.15
- AVTX N/A
- P/E Ratio
- HNVR $14.73
- AVTX N/A
- Revenue Growth
- HNVR 14.14
- AVTX N/A
- 52 Week Low
- HNVR $17.86
- AVTX $3.39
- 52 Week High
- HNVR $27.14
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- HNVR N/A
- AVTX 67.13
- Support Level
- HNVR N/A
- AVTX $13.42
- Resistance Level
- HNVR N/A
- AVTX $14.73
- Average True Range (ATR)
- HNVR 0.00
- AVTX 0.91
- MACD
- HNVR 0.00
- AVTX 0.12
- Stochastic Oscillator
- HNVR 0.00
- AVTX 78.78
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).